At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
ENV515-3 Travoprost XR +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
In Brief
A Phase 2 clinical trial evaluating ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, and 1 other intervention for Glaucoma and Ocular Hypertension. Completed, enrolled 41 participants across 14 sites.
Detailed Summary
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma and Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedFeb 2015
Primary CompletionFeb 2019
TodayJul 2026
First PostedFeb 26, 2015
Enrollment StartJan 1, 2015
Primary CompletionFeb 13, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.3 years ago
Interventions
ENV515-3 Travoprost XRdrug
ENV515-1 Travoprost XRdrug
ENV515-3-2 Travoprost XRdrug